舌下免疫治疗中患者自感依从性与就医障碍
本研究通过回顾性分析,识别出46例基于取药频率依从性未达优秀的含水舌下免疫治疗(SLIT)患者,其中28例完成电话调查;另调查56例提前退出治疗者。结果显示,28例中24例(86%)报告症状主观改善,19例(68%)自感依从性优秀,18例(65%)认为就诊不便是不依从主因;退出治疗最常见原因为费用(27%)、疗效不佳(25%)和依从困难(14%)。
要点
- 含水SLIT患者中多数自感依从性优秀,但基于取药频率并未达到优秀标准。
- 就诊安排不便和费用是患者报告的最常见就医障碍。
- 尽管依从性未达优秀,82%的患者报告症状改善。
核心结论
- 多数含水SLIT患者自感依从性优秀,但基于既往研究这些患者并未达到优秀依从性基准。
- 就诊不便和治疗费用是最常见的就医障碍。
- 尽管医生认为依从性未达优秀,82%的患者报告症状改善。
研究设计与样本
- 回顾性研究,基于取药就诊频率识别46例依从性未达优秀的正在接受含水SLIT的患者。
- 28例患者完成关于症状改善、依从性和就医障碍的电话调查。
- 56例提前退出治疗的患者接受关于依从障碍的调查。
主要发现
- 28例完成电话调查的患者中,24例(86%)报告SLIT期间症状主观改善。
- 28例中19例(68%)自感依从性优秀。
- 28例中18例(65%)报告预约和就诊不便是不依从的主要原因。
- 退出治疗最常见原因为费用(27%)、疗效不佳(25%)和依从困难(14%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For allergy immunotherapy to be effective, patient compliance is critical. However, aqueous sublingual immunotherapy (SLIT) may be considered demanding for patients, requiring strict daily dosing and refilling of medication at regular intervals. In this study we sought to determine how patients perceive their own compliance with SLIT and identify barriers that may hinder compliance. METHODS: Using a retrospective review, 46 patients currently undergoing aqueous SLIT were identified to have less-than-excellent compliance based on frequency of clinic visits for SLIT refills. Twenty-eight of these patients completed a phone survey regarding symptom improvement, compliance, and barriers to care. In addition, 56 patients who withdrew from therapy before completion were polled about barriers to adherence. RESULTS: Of the 28 patients participating in the initial phone survey, 24 (86%) reported subjective improvement in symptoms on SLIT, despite less-than-excellent compliance. Nineteen (68%) of these patients perceived their own compliance to be excellent. Eighteen patients (65%) reported the inconvenience of scheduling and attending clinic appointments to be the main reason for noncompliance. The most common reasons for withdrawal from therapy were cost (27%), lack of effectiveness (25%), and difficulty with compliance (14%). CONCLUSION: The majority of aqueous SLIT patients perceived their compliance to be excellent, although, based on a previous study, these patients did not reach excellent compliance benchmarks. Inconvenience of clinic visits and cost of therapy were found to be the most common barriers to care. Despite what providers perceived as less-than-excellent compliance, 82% of patients reported symptom improvement with SLIT.
引用
- Kumar MS, Oh MS, Leader B, et al. Perceived compliance and barriers to care in sublingual immunotherapy. Int Forum Allergy Rhinol. 2017. PMID: 28182329. doi:10.1002/alr.21920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。